688513 Chengdu Easton Biopharmaceuticals
- 58.02
- -0.58-0.99%
Chengdu Easton Biopharmaceuticals News
Yuandong Biotech (688513.SH): 0.9086% of shares have been repurchased
Gelonghui, May 6, 丨 Yuandong Biotech (688513.SH) announced that by the end of April 2024, the company had repurchased a total of 1,092 shares of the company through centralized bidding transactions, accounting for 0.9086% of the company's total share capital. The highest purchase price was 56.05 yuan/share, the lowest price was 43.5 yuan/share, and the total transaction amount was RMB 54,282,923.09 (excluding transaction fees such as stamp duty and transaction fees).
Yuandong Biotech (688513.SH): Phase III clinical trial of eugliptin tablets as a single agent to treat type 2 diabetes reached the expected goals
Gelonghui, April 30丨Yuandong Biology (688513.SH) announced that the phase III clinical trial of the self-developed Class 1 new drug eugliptin tablets to treat type 2 diabetes as a single agent has recently obtained a clinical trial summary report and achieved the expected goals. Phase III clinical trial results showed that euglithin tablets can significantly improve glycated hemoglobin (HbA1c), fasting blood sugar, and blood sugar 2 hours after meals in patients with type 2 diabetes who have poor exercise control on a simple diet. Euglitine tablets as a single drug treatment for Chinese type 2 diabetics with poor exercise control on a simple diet can significantly improve patients' glycated hemoglobin, fasting blood sugar, and after meals2
Yuandong Biotech (688513.SH) plans to launch 2024 employee stock ownership plan
Yuandong Biotech (688513.SH) disclosed the 2024 employee stock ownership plan (draft). The number of participants was no more than 208, and the total amount of capital to be raised was no more than 346.938 million yuan. Using “shares” as the subscription unit, each share was 1 yuan. The maximum number of shares in the employee shareholding plan was 346.938 million shares. The final total amount of capital raised was based on the actual total amount of capital raised. The source of shares in the employee stock ownership plan is Yuandong Biotech's A-share common stock shares in the company's repurchase special securities account. After the employee shareholding plan is reviewed and approved by the company's shareholders' meeting, the company will be obtained through non-transactional transfers and other methods permitted by laws and regulations
Yuandong Biology (688513): A variety of potential new products have been approved, and the internationalization of formulations opens up room for long-term growth
Performance summary: For the full year of 2023, the company achieved operating income of 1,117 million yuan (-4.56%), net profit attributable to mother of 227 million yuan (-8.09%), and net profit not attributable to mother of 158 million yuan (-4.32%)
Guojin Securities released a research report on April 24 stating that Yuandong Biotech (688513.SH) was given an increased rating. The main reasons for the rating include: 1) the risk of collection is gradually being clarified, and the anesthesia pipeline
Guojin Securities released a research report on April 24 stating that Yuandong Biotech (688513.SH) was given an increased rating. The main reasons for the rating include: 1) the risk of collection is gradually being clarified, and the anesthesia pipeline is strengthened; 2) the development of high-end formulations and the full internationalization of raw materials. (Mainichi Keizai Shimbun)
Chengdu Easton Biopharmaceuticals Co., Ltd. (SHSE:688513) Adds CN¥461m in Market Cap and Insiders Have a 49% Stake in That Gain
Key Insights Significant insider control over Chengdu Easton Biopharmaceuticals implies vested interests in company growth The top 3 shareholders own 50% of the company Using data from analyst for
Ping An Securities released a research report on April 23 stating that it gave Yuandong Biology (688513.SH) a recommended rating. The main reasons for the rating include: 1) the company's collection risk is basically clear; 2) the refined hemp specialty i
Ping An Securities released a research report on April 23 stating that it gave Yuandong Biology (688513.SH) a recommended rating. The main reasons for the rating include: 1) the company's collection risk is basically clear; 2) the refined hemp specialty innovation pipeline continues to advance, which is expected to usher in intensive catalysis in the short to medium term; 3) specialty hemp injections go overseas, driving the company's long-term growth. (Mainichi Keizai Shimbun)
Yuandong Biology (688513): Building the foundation for large single refined cannabis products+internationalization of formulations drives long-term growth
Matters: The company announced its 2023 annual report, achieving revenue of 1,117 million yuan (-4.6%), net profit attributable to mother of 227 million yuan (-8.1%), net profit after deduction of 158 million yuan (-4.3%), performance omitted
Yuandong Biotech (688513.SH) announced its 2023 annual results, with net profit of 227 million yuan, a year-on-year decrease of 8.09%
Yuandong Biotech (688513.SH) disclosed its 2023 annual report. The company achieved revenue of 1,117 billion yuan in 2023, a year-on-year decrease of 4.56%; net profit to mother was 227 million yuan, a year-on-year decrease of 8.09%; after deducting non-net profit of 158 million yuan, a year-on-year decrease of 4.32%. Basic earnings per share were $1.89. It is proposed to distribute a cash dividend of 5.8 yuan (tax included) for every 10 shares, and the capital reserve will be used to transfer 4.7 shares for every 10 shares to all shareholders.
Yuandong Biology (688513) Commentary on important matters: Nabuphine and butorphinol were successively approved, and the refined hemp layout ushered in harvest
Matters: Recently, the company issued an announcement. Butorphinol tartrate injection was approved by NMPA. Previously, on March 1, the company's naburpine hydrochloride injection was also approved by the NMPA. The company has already launched two anesthetic analgesia products
Easton Biopharma's Unit Gets Nod to Market Bisoprolol Amlodipine Tablets
Chengdu Easton Biopharmaceuticals' (SHA:688513) unit, Chengdu Shuode Pharmaceutical, obtained a drug registration certificate from China's National Medical Products Administration for its bisoprolol a
Express News | Yuandong Biology: Bisoprolol amlodipine tablets obtained drug registration certificate
Express News | Yuandong Biology: Butorphinol Tartrate Injection Obtains Drug Registration Certificate
Yuandong Biotech (688513.SH): A total of 0.9086% of the company's shares have been purchased at a cost of 54.282,900 yuan
Gelonghui, April 2, 丨 Yuandong Biotech (688513.SH) announced that by the end of March 2024, the company had repurchased a total of 1.0911 million shares through centralized bidding transactions, accounting for 0.9086% of the company's total share capital. The highest purchase price was 56.05 yuan/share, the lowest price was 43.5 yuan/share, and the total transaction amount was RMB 54.2829 million (excluding transaction fees such as stamp duty and transaction fees).
Yuandong Biotech (688513.SH): Preliminary determination that the inquiry transfer price was 51.5 yuan/share. The transferees were 7 institutional investors
Yuandong Biotech (688513.SH) disclosed shareholders' inquiries and transfer pricing. After inquiring with institutional investors, preliminary...
Yuandong Biotech (688513.SH): Shareholders plan to transfer 2.7% of shares in an inquiry
Gelonghui, March 29丨Yuandong Biotech (688513.SH) announced that it intends to participate in Yuandong Biotech's initial shareholder inquiry and transfer. The shareholders are Chengdu Nanyuan Investment Partnership (limited partnership), Chengdu Zhuyuan Investment Partnership (limited partnership), and Chengdu Juyuan Investment Partnership (limited partnership); the total number of shares to be transferred by the seller is 3,240,000 shares, accounting for 2.70% of Yuandong Biotech's total share capital; this inquiry transfer is an undisclosed transfer and will not be carried out through centralized bidding. The transferee transfers the transferred shares through an inquiry, and cannot be transferred within 6 months after the transfer.
Yuandong Biology (688513.SH): Received a government subsidy of 35.5084 million yuan related to revenue
Gelonghui March 22丨Yuandong Biology (688513.SH) announced that the company and its wholly-owned subsidiaries Tibet Runhe Pharmaceutical Co., Ltd., Sichuan Sunshine Runhe Pharmaceutical Co., Ltd., Chengdu Shuode Pharmaceutical Co., Ltd., Sichuan Aoki Pharmaceutical Co., Ltd., and Chengdu Yuluo Biotechnology Co., Ltd. have received a total of RMB 35.5084 million in government grants related to revenue from July 22, 2023 to March 21, 2024.
Yuandong Biology (688513) Follow-up Analysis Report: Internationalization and Fine Hemp Line Fulfill Business Development Welcome Cycle
Internationalization and refinement pipelines are realized, and business development welcomes a new cycle. As a pharmaceutical platform driven by R&D innovation and integrating API formulations, Yuandong Biotech has extensive internal accumulation. Over the past five years, the company's R&D expense ratio has remained at 1
Is Chengdu Easton Biopharmaceuticals (SHSE:688513) Using Too Much Debt?
Howard Marks put it nicely when he said that, rather than worrying about share price volatility, 'The possibility of permanent loss is the risk I worry about... and every practical investor I know wor
Yuandong Biotech (688513.SH): A total cost of 54.28 million yuan to buy back 0.9% of the shares
Gelonghui, March 1, 丨 Yuandong Biotech (688513.SH) announced that by the end of February 2024, Chengdu Yuandong Biopharmaceutical Co., Ltd. had repurchased a total of 1,092 shares of the company through centralized bidding transactions, accounting for 0.9086% of the company's total share capital. The highest purchase price was 56.05 yuan/share, the lowest price was 43.5 yuan/share, and the total transaction amount was RMB 54,282,923.09.
Analysis
Price Target
No Data
